3.7 Mucolytics

Carbocisteine
  • Capsules 375mg (£15.69 = 2.25g daily)
  • Sachets 750mg/10ml sugar-free oral solution (£21.56= 2.25g daily)

Indications

  • COPD patients with a chronic cough productive of sputum

Dose

  • Initially 2.25g daily in divided doses, then 1.5g daily in divided doses as condition improves

Notes

  1. Mucolytic therapy can be considered for patients with a chronic productive cough and continued only if there is symptomatic improvement following a 4-week trial.
Dornase alfa
  • Nebuliser solution 1,000 units/ml

Indications

  • Cystic fibrosis

Notes

  1. For use undiluted with jet nebulisers only; ultrasonic nebulisers are unsuitable
Ivacaftor
  • Tablets 150mg

Notes

  1. See NHS England Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis
Lumacaftor/Ivacaftor (Orkambi®)
  • NICE TA398 Lumacaftor-ivacaftor is not recommended for treating cystic fibrosis homozygous for the F508del mutation (July 2016)

Mannitol

Mannitol
  • Inhalation powder, hard capsule 40mg

Notes

  1. See NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (November 2012)

 

Home > Formulary > Chapters > 3. Respiratory > 3.7 Mucolytics

 

  • First line
  • Second line
  • Specialist
  • Hospital